Hasten Biopharmaceutical Co., Ltd. (Hasten) and China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. reached a strategic cooperation at the 6th CIIE on November 7th of 2023.
-- Hasten obtains rights to develop and commercialize lerodalcibep in Chinese Mainland, Hong Kong, Macau, and Taiwan and will be responsible for clinical development and regulatory approval in these territories
On July 11th, the "2023 Beijing International Life and Health Industry Cross-border Expo, Life and Health Innovators Annual Conference" was officially opened at the China International Exhibition Center in Beijing. With the theme of "4D Rules of Innovation Track", the branch ceremony, “Life and Health Innovators Annual Conference" organized by SiqiQuan, was launched there simultaneously.
The jointly organized by China Pharmaceutical Business Association and Sinopharm Global Procurement and Supply Chain Service Center was held in Shanghai recently. Mr. Kevin Gu, Senior Vice President, Head of Market Access, Commercial Diversity & International Business of Hasten Biopharmaceutical Co., Ltd. was invited to attend the conference and delivered a speech on "Exploring Supply Chain Integration Development for Innovative Pharmaceutical Enterprises".
Shanghai, May 4th , 2023 – Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche.
20 April, 2023 – CBC Group (“CBC”), Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, and Hasten Biopharmaceutic Company Limited (“Hasten”), today jointly announced the completion of a US$315 million fundraising round for Hasten. Hasten is an innovation-driven pharmaceutical company backed by CBC, Hefei Industry Investment Group, and Feidong County of Hefei City.